Research programme: selective androgen receptor modulators - Ligand Pharmaceuticals

Drug Profile

Research programme: selective androgen receptor modulators - Ligand Pharmaceuticals

Alternative Names: LG 123129; LG 123303; LGD-3129; LGD-3303

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Ligand Pharmaceuticals; Viking Therapeutics
  • Class Quinolones
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cachexia; Female sexual dysfunction; Male sexual dysfunction; Osteoporosis
  • No development reported Hypogonadism

Most Recent Events

  • 23 Mar 2017 Preclinical development is ongoing for Cachexia, Female-sexual dysfunction, Male sexual dysfunction and Osteoporosis in USA
  • 23 Mar 2017 Viking Therapeutics has patent protection and pending patent applications for selective androgen receptor modulators in USA, Canada, India, Japan, Korea, Mexico, Australia, China, New Zealand, Argentina, Brazil, Europe and Israel
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cachexia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top